The FDA approved the norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo, Viatris Inc), a once-weekly combined hormonal contraceptive patch, based on phase 3 data on efficacy, safety, and...
The FDA approved two new oral therapies to treat uncomplicated urogenital gonorrhea. Both treatments demonstrated comparable effectives when compared to standard treatment.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
